SCHEMBL6840897

SCHEMBL6840897

CCOC(=O)c1cc(Oc2ccc3ccccc3c2)cc(C(=O)O)c1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGS2 P35354 2/20 0.55
F2 P00734 1/20 0.49
F10 P00742 1/20 0.49
CYP2C9 P11712 2/20 0.47
CYP2C19 P33261 1/20 0.47
MAPT P10636 4/20 0.46
MEN1 O00255 3/20 0.46
KMT2A Q03164 3/20 0.46
TDP1 Q9NUW8 1/20 0.46
CA12 O43570 1/20 0.45
CA1 P00915 1/20 0.45
CA2 P00918 1/20 0.45
CA7 P43166 1/20 0.45
CA9 Q16790 1/20 0.45
CA14 Q9ULX7 1/20 0.45
NPSR1 Q6W5P4 1/20 0.45
NPC1 O15118 2/20 0.45
RAB9A P51151 2/20 0.45
KDM4E B2RXH2 1/20 0.45
ALDH1A1 P00352 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6843239 0.86 AKR1C3 (0.58) MAPTMEN1KMT2ATDP1KDM4E
SCHEMBL6840905 0.83 CTRC (0.54) CYP2C9CYP2C19MAPTMEN1KMT2A
SCHEMBL6840894 0.79 SIRT2 (0.51) MAPTMEN1KMT2ATDP1CA12
SCHEMBL7116149 0.78 USP2 (0.48) F2F10CYP2C9CYP2C19MAPT
SCHEMBL3327442 0.78 CYP2C19 (0.70) CYP2C9CYP2C19MAPTMEN1KMT2A
SCHEMBL7234951 0.78 CYP2C19 (0.70) CYP2C9CYP2C19MAPTMEN1KMT2A
SCHEMBL30684671 0.77 CA12 (0.59) MAPTMEN1KMT2ACA12CA1
SCHEMBL571295 0.77 CA12 (0.59) MAPTMEN1KMT2ACA12CA1
SCHEMBL22660964 0.76 CYP2C19 (0.68) CYP2C9CYP2C19MAPTMEN1KMT2A
Ammonia Solution, Strong SCHEMBL28298874 0.76 CYP2C19 (0.68) CYP2C9CYP2C19MAPTMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040157919-A1 Trisubstituted carbocyclic cyclophilin binding compounds and their use WU YONG-QIAN (US) 2004-08-12 US disclosed
US-6656971-B2 Non-peptidic small organic compounds having an affinity for cyclophilin (CyP)-type immunophilins; inhibiting their peptidyl-prolyl isomerase activity; treating variety of medical conditions GUILFORD PHARMACEUTICALS INC. 2003-12-02 US disclosed
EP-1360173-A2 TRISUBSTITUTED CARBOCYCLIC CYCLOPHILIN BINDING COMPOUNDS AND THEIR USE GUILFORD PHARMACEUTICALS INC. (US) 2003-11-12 EP disclosed
US-20020165275-A1 Trisubstituted carbocyclic cyclophilin binding compounds and their use GUILFORD PHARMACEUTICALS INC. 2002-11-07 US disclosed
WO-2002059080-A2 TRISUBSTITUTED CARBOCYCLIC CYCLOPHILIN BINDING COMPOUNDS AND THEIR USE GUILFORD PHARMACEUTICALS INC. (US) 2002-08-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040157919-A1 Trisubstituted carbocyclic cyclophilin binding compounds and their use FKBP2, PPIG, FKBP8 PTGS2 337/4885F2 1169/4885F10 3056/4885
US-20020165275-A1 Trisubstituted carbocyclic cyclophilin binding compounds and their use FKBP2, PPIG, FKBP8 PTGS2 337/4885F2 1169/4885F10 3056/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.